ERBB2 and breast cancer: These findings emphasize that Shc3 overexpression enhances ErbB2 translocation and activates the ErbB2‐COX2‐MDR1 axis, which contributes to the initiation and progression of MDR and aggressive behavior in breast cancer cells.